Skip to main content
Premium Trial:

Request an Annual Quote

MGI Tech, Pillar Biosciences Sign Comarketing Agreement for NGS Panels

NEW YORK – Pillar Biosciences said today that it has signed a comarketing agreement with China's MGI Tech for its Onco/Reveal next-generation sequencing panels.

Under the terms of the agreement, MGI, which markets the MGISP-960 and -100 automated high-throughput library prep systems, will market the Pillar panels to its sequencing customers outside the US.

"With MGI's sample prep automation, the hands-on time for our simplified library prep workflows has reached an unprecedented level of efficiency," Pillar CEO Gang Song said in a statement.

Boston-based Pillar said that its NGS panels featuring SLIMamp target enrichment chemistry are now compatible with the MGI, Illumina, and Thermo Fisher Scientific Ion Torrent sequencing platforms.

The comarketing deal is the second in as many weeks for MGI — the BGI subsidiary signed a similar deal with Twist Bioscience Oct. 30, covering target enrichment products in the Europe and Asia Pacific regions.

Pillar announced a strategic partnership and joint venture with China Biotech Services Holdings in January.

"This agreement combines two technologies that really complement each other," added MGI President Duncan Yu. "We're excited to work with Pillar to deliver seamlessly integrated automated library preparation."

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.